L26/P-666 Preliminary results of expanded carrier screening in a large Georgian cohort
Human Reproduction · 01.07.2026 · 41 (Supplement_1)
DOI: 10.1093/humrep/deag083.996 ↗Kurz gefasst
Fachartikel in der Zeitschrift Human Reproduction, online erschienen am 08.07.2026. Verfasst von M. Melikishvili und 11 weiteren Autor:innen.
Abstract (Originalsprache)
Study question What is the burden and population-specific distribution of actionable carrier states identified by expanded carrier screening in the Georgian population? Summary answer Expanded carrier screening revealed a high burden of actionable carrier states with enrichment of several reproductive risk genes, supporting its clinical utility in Georgia. What is known already Expanded carrier screening (ECS) is increasingly used in reproductive medicine to identify individuals and couples at risk of transmitting severe inherited disorders. Carrier frequencies vary across populations due to genetic, geographic, and historical factors. However, population-specific ECS data from the south caucasus region, including Georgia, remain limited, restricting evidence-based implementation. Study design, size, duration This retrospective observational study analyzed expanded carrier screening results collected in Georgia between 2023-till December 2025 from a total of 864 analyzed individuals. Participants/materials, setting, methods Expanded carrier screening was performed in 864 individuals using next-generation sequencing panels covering over 370 autosomal recessive and X-linked genes. Fragile X syndrome and spinal muscular atrophy were assessed using targeted non-NGS assays. Pathogenic and likely pathogenic variants were analyzed at individual and couple levels. Main results and the role of chance A total of 656 unique pathogenic or likely pathogenic variants across 249 genes were identified. At least one reportable finding was detected in 72.6% of singletons. Among 62 tested couples, 10 couples (16.1%) had findings with direct reproductive risk, including 7 autosomal recessive carrier couples and 3 couples with X-linked risk identified in the female partner. An additional 49 couples had positive findings without shared reproductive risk, while 3 couples had completely negative results, highlighting the clinical relevance of expanded carrier screening (ECS) for reproductive counseling. Several conditions demonstrated elevated carrier frequencies in the Georgian cohort. The most frequent findings involved CYP21A2 (10.1%), MEFV (8.1%), PAH (7.5%), CFTR (6.1%), and GJB2 (3.7%), together accounting for a substantial proportion of detected carrier states and indicating non-random enrichment of high-impact, clinically actionable conditions. Carrier frequencies for MEFV, PAH, CFTR, and GJB2 exceeded commonly reported global estimates, supporting population-specific enrichment consistent with regional Mediterranean–Caucasus genetic architecture. In contrast, the high apparent CYP21A2 carrier rate likely reflects frequent detection of duplicated gene haplotypes considered likely benign, underscoring the need for gene-specific interpretation. X-linked findings were identified in 3.2% of individuals, predominantly involving FMR1 intermediate and premutation alleles. Limitations, reasons for caution This study represents a preliminary analysis with a moderate sample size, limiting definitive population-level conclusions. The cohort was referral-based, introducing potential selection bias. Certain variants, particularly in CYP21A2, require cautious interpretation due to complex genomic architecture. Larger, prospective population-based studies are planned to validate and extend these findings. Wider implications of the findings These preliminary data provide the first large-scale ECS reference for Georgia and demonstrate meaningful reproductive risk stratification. The findings support integration of ECS into preconception care, complementary to newborn screening, guided by population-specific frequency data and refinement of a core set of high-impact genes to optimize clinical utility and cost-effectiveness. Trial registration number No
Zitieren
APA
Melikishvili, M., Tabatadze, N., Chipashvili, M., Kurashvili, N., Tughushi, T., Museridze, N., Kvaliashvili, S., Guo, C., Mendiratta-Vij, G., Gao, H., Neckelmann, C., & Rofoogaran, A. (2026). L26/P-666 Preliminary results of expanded carrier screening in a large Georgian cohort. Human Reproduction, 41(Supplement_1). https://doi.org/10.1093/humrep/deag083.996
Vancouver
Melikishvili M, Tabatadze N, Chipashvili M, Kurashvili N, Tughushi T, Museridze N, et al. L26/P-666 Preliminary results of expanded carrier screening in a large Georgian cohort. Human Reproduction. 2026;41(Supplement_1). doi:10.1093/humrep/deag083.996
BibTeX
@article{Melikishvili2026,
author = {Melikishvili, M. and Tabatadze, N. and Chipashvili, M. and Kurashvili, N. and Tughushi, T. and Museridze, N. and Kvaliashvili, S. and Guo, C. and Mendiratta-Vij, G. and Gao, H. and Neckelmann, C. and Rofoogaran, A.},
title = {L26/P-666 Preliminary results of expanded carrier screening in a large Georgian cohort},
journal = {Human Reproduction},
year = {2026},
volume = {41},
number = {Supplement_1},
doi = {10.1093/humrep/deag083.996}
}
EUVIMED